

fect of drugs on renal outcomes in patients with heart failure.³

Milton Packer, M.D.

Baylor University Medical Center
Dallas, TX
milton.packer@baylorhealth.edu

Javed Butler, M.D., M.P.H.

University of Mississippi School of Medicine
Jackson, MS

Faiez Zannad, M.D., Ph.D.

Université de Lorraine
Nancy, France

and Others

for the EMPEROR Study Group

A complete list of authors is available with the full text of this letter at NEJM.org.

Supported by Boehringer Ingelheim and Eli Lilly.

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

Data will be made available on request in adherence with transparency conventions in medical research and through re-

quests to the corresponding author. Following execution of pre-specified analyses, a full database will be made available in adherence with the transparency policy of the sponsor (available at https://trials.boehringer-ingenelheim.com/transparency_policy.html).

This letter was published on August 27, 2021, at NEJM.org.

1. Jhund PS, Solomon SD, Docherty KF, et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. *Circulation* 2021;143:298-309.
2. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med* 2020; 383:1413-24.
3. Packer M. Pitfalls in using estimated glomerular filtration rate slope as a surrogate for the effect of drugs on the risk of serious adverse renal outcomes in clinical trials of patients with heart failure. *Circ Heart Fail* 2021;14(6):e008537.
4. Packer M, Butler J, Filippatos G, et al. Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. *Eur J Heart Fail* 2020;22:2393-8.
5. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med* 2021; 385:1451-61.

DOI: 10.1056/NEJMc2112411

Receipt of mRNA Covid-19 Vaccines and Risk of Spontaneous Abortion

TO THE EDITOR: Pregnant persons are at risk for severe coronavirus disease 2019 (Covid-19), and infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy is associated with increased risks of preterm birth and other adverse maternal and neonatal outcomes.¹ Although spontaneous abortion (pregnancy loss occurring at less than 20 weeks of gestation) is a common pregnancy outcome affecting 11 to 22% of recognized pregnancies (see Table S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org),^{2,4} data to inform estimates of the risk of spontaneous abortion after receipt of an mRNA Covid-19 vaccine either before conception (30 days before the first day of the last menstrual period through 14 days after) or during pregnancy are limited.

We analyzed data from the Centers for Disease Control and Prevention (CDC) v-safe Covid-19 vaccine pregnancy registry to determine the cumulative risk of spontaneous abortion from 6 to less than 20 weeks of gestation. Participants with a singleton pregnancy who had received at least one dose of an mRNA Covid-19 vaccine either before conception or before 20 weeks of gestation and who did not have a pregnancy loss before 6 weeks of gestation were included in this analysis. Inclusion of pregnant participants at 6 weeks of gestation is consistent with literature estimating

the risk of spontaneous abortion in the general population.^{2,4} Life table methods were used to calculate the cumulative risk of spontaneous abortion according to gestational week, with appropriate left truncation (i.e., with adjustment for gestational age at entry); data were right-censored at the time of the most recent contact for participants with ongoing pregnancies who were not contacted at 20 weeks of gestation or later and at the time of the outcome for participants who reported pregnancy outcomes other than spontaneous abortion (induced abortions or ectopic or molar pregnancies) before 20 weeks of gestation. The cumulative risk of spontaneous abortion was also age-standardized with the use of data on the risk of spontaneous abortion according to maternal age group.³ We conducted a sensitivity analysis to estimate the maximum possible risk of spontaneous abortion, using an extreme assumption that all participants whose most recent contact was during the first trimester (i.e., at less than 14 weeks of gestation) and whom we were unable to reach during the second trimester experienced a spontaneous abortion immediately after the most recent contact (see the Supplementary Appendix for details).

A total of 2456 participants who were enrolled in the CDC v-safe Covid-19 pregnancy registry met the inclusion criteria for this study;

Table 1. Risk of Spontaneous Abortion among Participants in the v-safe Covid-19 Vaccine Pregnancy Registry, December 14, 2020, through July 19, 2021.

Gestational Age	Participants at Risk	Participants Who Reported Spontaneous Abortion	Week-Specific Risk	Cumulative Risk
		<i>number of persons</i>	<i>percent</i>	<i>percent (95% CI)</i>
6 to <7 weeks	904	15	1.7	1.7 (0.8–2.5)
7 to <8 weeks	982	18	1.8	3.5 (2.3–4.6)
8 to <9 weeks	1032	37	3.6	6.9 (5.4–8.5)
9 to <10 weeks	1087	39	3.6	10.3 (8.4–12.0)
10 to <11 weeks	1118	19	1.7	11.8 (9.9–13.7)
11 to <12 weeks	1184	12	1.0	12.7 (10.7–14.6)
12 to <13 weeks	1274	9	0.7	13.3 (11.3–15.2)
13 to <14 weeks	1394	5	0.4	13.6 (11.6–15.6)
14 to <15 weeks	1534	0	0	13.6 (11.6–15.6)
15 to <16 weeks	1632	2	0.1	13.7 (11.7–15.7)
16 to <17 weeks	1742	2	0.1	13.8 (11.8–15.8)
17 to <18 weeks	1848	2	0.1	13.9 (11.9–15.9)
18 to <19 weeks	1941	3	0.2	14.0 (12.0–16.0)
19 to <20 weeks	2052	2	0.1	14.1 (12.1–16.1)

2022 participants reported ongoing pregnancies at 20 weeks of gestation, 165 participants reported a spontaneous abortion (154 participants before 14 weeks of gestation), 65 participants with most recent contact during the first trimester could not be reached for second trimester follow-up, 188 participants completed second trimester follow-up before 20 weeks of gestation, and 16 participants reported another pregnancy outcome before 20 weeks (induced abortion or ectopic or molar pregnancy) (Fig. S1). Most participants were 30 years of age or older (77.3%), were non-Hispanic White (78.3%), and worked as health care personnel (88.8%). Slightly more than half the participants (52.7%) had received the BNT162b2 vaccine (Pfizer–BioNTech) (Table S2). The cumulative risk of spontaneous abortion from 6 to less than 20 weeks of gestation was 14.1% (95% confidence interval [CI], 12.1 to 16.1) in the primary analysis (Table 1) and 12.8% (95% CI, 10.8 to 14.8) in an analysis using direct maternal age–standardization to the reference population. The cumulative risk of spontaneous abortion increased with maternal age (Table S3). In the sensitivity analysis, under the extreme assumption that all 65 participants with most recent contact during the first trimester had a spontaneous abortion, the cumulative risk of spontaneous abortion from 6 to less than 20 weeks of gestation was 18.8% (95% CI, 16.6 to 20.9); after age standardization, the cumulative risk was 18.5% (95% CI, 16.1 to 20.8).

As compared with data from two historical cohorts that represent the lower and upper ranges of spontaneous-abortion risk,^{2,4} the cumulative risks of spontaneous abortion from our primary and sensitivity analyses were within the expected risk range (Fig. 1). Limitations of our study include the lack of a control group of unvaccinated pregnant persons, the homogeneity of the participants in terms of racial and ethnic groups and occupation, the voluntary enrollment of the population, and the use of data reported by the participants themselves, including some data collected retrospectively. Nonetheless, our findings suggest that the risk of spontaneous abortion after mRNA Covid-19 vaccination either before conception or during pregnancy is consistent with the expected risk of spontaneous abortion; these findings add to the accumulating evidence about the safety of mRNA Covid-19 vaccination in pregnancy.⁵

Lauren H. Zauche, Ph.D., M.S.N.

Bailey Wallace, M.P.H.

Sascha R. Ellington, Ph.D., M.S.P.H.*

Centers for Disease Control and Prevention

Atlanta, GA

vsafecallctr@cdc.gov


and Others

for the CDC v-safe Covid-19 Pregnancy Registry Team

*The members of the CDC v-safe Covid-19 Pregnancy Registry Team are listed in the Supplementary Appendix.

A complete list of authors is available with the full text of this letter at NEJM.org.

The findings and conclusions in this letter are those of the authors and do not necessarily represent the official position of



the Centers for Disease Control and Prevention (CDC). Mention of a product or company name is for identification purposes only and does not constitute endorsement by the CDC or the Food and Drug Administration. The authors do not have any material conflicts of interest.

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

This letter was published on September 8, 2021, at NEJM.org.

1. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. *BMJ* 2020;370:m3320.
2. Mukherjee S, Velez Edwards DR, Baird DD, Savitz DA, Hart-

mann KE. Risk of miscarriage among black women and white women in a U.S. prospective cohort study. *Am J Epidemiol* 2013; 177:1271-8.

3. Magnus MC, Wilcox AJ, Morken N-H, Weinberg CR, Håberg SE. Role of maternal age and pregnancy history in risk of miscarriage: prospective register based study. *BMJ* 2019;364:l869.

4. Goldhaber MK, Fireman BH. The fetal life table revisited: spontaneous abortion rates in three Kaiser Permanente cohorts. *Epidemiology* 1991;2:33-9.

5. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. *N Engl J Med* 2021;384:2273-82.

DOI: 10.1056/NEJMc2113891

On Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

TO THE EDITOR: Shimabukuro et al. (June 17 issue)¹ reported preliminary data on the safety of messenger RNA (mRNA) Covid-19 vaccines in pregnancy from the v-safe surveillance system and pregnancy registry. They reported that among 827 participants with a completed pregnancy, the pregnancy resulted in spontaneous abortion by week 20 in 104 (12.6%), and the authors indicated that this proportion was similar to that in the general population. This calculated metric is misleading and does not reflect the real risk of spontaneous abortion.

As stated in the article, among the 827 participants with a completed pregnancy, 700 received their first eligible vaccine dose in the third trimester. These participants should be excluded from the calculation because they had already

passed week 20 when they received the vaccination. The risk of spontaneous abortion should be determined on the basis of the group of participants who received the vaccination before week 20 and were followed through week 20 or had an earlier pregnancy loss. Comparison with population-based rates of spontaneous abortion is complicated by the fact that women who are vaccinated at later times during early pregnancy have less time during which they are at risk for pregnancy loss; thus, a crude proportion is likely to underestimate the overall risk.²

Hong Sun, Ph.D.

Dedalus Healthcare
Antwerp, Belgium

No potential conflict of interest relevant to this letter was reported.